The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. (Q37423754)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

review article

1 reference

title

The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

main subject

cardiovascular disease

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Eun Y Oh

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Hi B Lee

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

language of work or name

English

0 references

publication date

1 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Nephrology

24 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

203-211

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

PAI-1 antagonists: predictable indications and unconventional applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Regulation and interactions in the activation of cell-associated plasminogen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Molecular mechanisms of fibrinolysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Circadian variation and triggers of onset of acute cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Circadian variation in the efficacy of tissue-type plasminogen activator.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

The transforming growth factor-beta family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

The plasminogen activator system: biology and regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Sp1 Sites Mediate Activation of the Plasminogen Activator Inhibitor-1 Promoter by Glucose in Vascular Smooth Muscle Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Reactive oxygen species mediate TGF-beta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Antioxidant effect of adrenomedullin on angiotensin II-induced reactive oxygen species generation in vascular smooth muscle cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Adrenomedullin inhibits angiotensin II-induced oxidative stress and gene expression in rat endothelial cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Transforming Growth Factor-β-Dependent and -Independent Pathways of Induction of Tubulointerstitial Fibrosis in β6−/− Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Essential features of a surveillance system to support the prevention and management of heart disease and stroke: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Stroke, and Cardiovascular Nursing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Proteinases and extracellular matrix remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Preconditioning and adenosine protect human proximal tubule cells in an in vitro model of ischemic injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Plasmin is not protective in experimental renal interstitial fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Urokinase receptor: a molecular organizer in cellular communication.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Modulation of adipose tissue development by pharmacological inhibition of PAI-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Characterization of a small molecule PAI-1 inhibitor, ZK4044.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Antihypertensive drugs and fibrinolytic function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Angiotensin II receptor blockade ameliorates mesangioproliferative glomerulonephritis in rats through suppression of CTGF and PAI-1, independently of the coagulation system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-beta1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Human cardiac microvascular and macrovascular endothelial cells respond differently to oxidatively modified LDL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Cellular Carbonyl Stress Enhances the Expression of Plasminogen Activator Inhibitor-1 in Rat White Adipocytes via Reactive Oxygen Species-dependent Pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.15

Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production

31 March 2020

1 reference

12 December 2020

Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.

1 reference

12 December 2020

Isolation and characterization of the rat plasminogen activator inhibitor-1 gene.

1 reference

12 December 2020

Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences

1 reference

12 December 2020

TNF-alpha and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes

1 reference

12 December 2020

Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease

1 reference

12 December 2020

The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis

1 reference

12 December 2020

The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.

1 reference

12 December 2020

Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies

1 reference

12 December 2020

Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients

1 reference

12 December 2020

Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene

1 reference

12 December 2020

Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against

1 reference

12 December 2020

The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy

1 reference

12 December 2020

Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2009.15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322185%20AND%20SRC:MED&resulttype=core&format=json

release_4ihgtrrxs5dfjjmf4jqd5kwh3i

24 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4ihgtrrxs5dfjjmf4jqd5kwh3i

24 November 2022

mapped directly with Wikidata item

1 reference